Ketolorac tromethamine should be available in September

Article

Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.

Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.

The new solution is formulated at pH 6.8 to enable deionized drug delivery on the corneal surface. It contains carboxymethylcellulose, a viscous molecule also found in one of the company's artificial tear formulations (Refresh Tears) and designed to enable the drug to adhere to the ocular surface and enhance patient comfort. Ketorolac tromethamine inhibits the cyclooxygenase (COX)-1 and COX-2 enzymes to hinder the development of prostaglandins, which are considered to be the primary sources of pain and inflammation following cataract surgery, the company said.

Patients administer one drop of the solution to the affected eye twice daily beginning the day before cataract surgery, then continue using the solution on the day of surgery and through the first 2 weeks of the postoperative period.

The efficacy of the solution was assessed in two multicentre, randomized, double-masked, parallel group comparison studies involving more than 500 patients receiving either ketorolac tromethamine or vehicle. Solution efficacy was defined as complete clearance of anterior chamber inflammation as measured by summed ocular inflammation score (SOIS) and ocular pain relief following cataract extraction with posterior chamber IOL implantation.

Results of these studies, according to the company, demonstrated that at day seven, 32% of patients receiving ketorolac tromethamine had an SOIS score of 0 compared with 17% of patients treated with vehicle. Also, according to Allergan, 53% of patients receiving the solution had clearing of anterior chamber inflammation at day 14 versus 26% of patients receiving vehicle. Additionally, on the first day after cataract surgery, the percentage of patients receiving ketorolac tromethamine who had a pain score of 0 was 72%, compared with 40% for patients in the vehicle group.

The most common adverse events, reported in 1% to 6% of patients, included increased IOP, conjunctival hyperemia and/or hemorrhage, corneal edema, ocular pain, headache, tearing, and blurred vision. Some of these events may have been the consequence of cataract surgery, according to Allergan.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.